• Trade
  • Markets
  • Copy
  • Contests
  • News
  • 24/7
  • Calendar
  • Q&A
  • Chats
Screeners
SYMBOL
LAST
ASK
BID
HIGH
LOW
NET CHG.
%CHG.
SPREAD
SPX
S&P 500 Index
6785.54
6785.54
6785.54
6857.86
6785.30
-97.18
-1.41%
--
DJI
Dow Jones Industrial Average
48878.89
48878.89
48878.89
49340.90
48878.89
-622.40
-1.26%
--
IXIC
NASDAQ Composite Index
22482.03
22482.03
22482.03
22841.28
22461.14
-422.54
-1.84%
--
USDX
US Dollar Index
97.630
97.710
97.630
97.750
97.440
+0.150
+ 0.15%
--
EURUSD
Euro / US Dollar
1.17972
1.17982
1.17972
1.18214
1.17800
-0.00073
-0.06%
--
GBPUSD
Pound Sterling / US Dollar
1.35386
1.35396
1.35386
1.36537
1.35331
-0.01133
-0.83%
--
XAUUSD
Gold / US Dollar
4818.46
4818.89
4818.46
5023.58
4788.42
-147.10
-2.96%
--
WTI
Light Sweet Crude Oil
62.739
62.769
62.739
64.398
62.725
-1.503
-2.34%
--

Community Accounts

Signal Accounts
--
Profit Accounts
--
Loss Accounts
--
View More

Become a signal provider

Sell trading signals to earn additional income

View More

Guide to Copy Trading

Get started with ease and confidence

View More

Signal Accounts for Members

All Signal Accounts

Best Return
  • Best Return
  • Best P/L
  • Best MDD
Past 1W
  • Past 1W
  • Past 1M
  • Past 1Y

All Contests

  • All
  • Trump Updates
  • Recommend
  • Stocks
  • Cryptocurrencies
  • Central Banks
  • Featured News
Top News Only
Share

U.S. Senate Majority Leader John Thune: The Senate’s Request For Funding For The Department Of Homeland Security (DhS) Is “unrealistic.”

Share

Colombia Public Credit Director Projects Domestic Debt Issuance Of 85.2 Trillion Pesos In 2026

Share

U.S. Treasury Secretary Bessenter Reiterated His Statement Made On February 4 Before The House Financial Services Committee At A Hearing Of The Senate Banking Committee

Share

[Ethereum Breaks Below $2000 After 273 Days, Down 8.2% In 24 Hours] February 5Th, According To Htx Market Data, Ethereum Fell Below $2000 After 273 Days, With A 24-Hour Decrease Of 8.2%, Marking The First Time Since May 8, 2025

Share

U.S. Ambassador To Poland Tom Rose Announced That He Would Sever All Ties With Polish Sejm Speaker Włodzimierz Czarzasty. The Diplomat Claimed That The Speaker's Remarks Were A "direct Offense" To U.S. President Trump And Detrimental To Polish Prime Minister Tusk, Who Has Called Trump "Dad," And His Government's "excellent Relationship" With The U.S

Share

Shell CEO Says Legal Proceedings In Kazakhstan Impact Our Appetite To Invest Further There

Share

The S&P 500 Index Fell Further To 1.1%

Share

U.S. Department Of Defense: The United States And Russia Have Agreed To Resume Military Dialogue

Share

The U.S. Global Supply Chain Stress Index For January Was 0.41, Revised From 0.51 To 0.54 In The Previous Month

Share

Bitcoin Drops Below $69000, Lowest Since November 2024, Last Down 5% At $68.905

Share

Qatar Sets March Marine Crude Osp At Oman/Dubai Minus $1.00/Bbl, Land Crude Osp At Oman/Dubai Plus $0.80/Bbl

Share

US President Trump: The Nigerian Government Must Be "tougher"

Share

Shell CEO Says Oil Market Supply Slightly Long, Balanced By Geopolitical Risk Like Venezuela And Iran

Share

Colombia Public Credit Director: Last Week We Made Massive Purchases Of Dollars

Share

Two-Year USA Treasury Yields Last Down 6.8 Basis Points At 3.492%

Share

US President Trump: We Are Working To End The War In Sudan, And It Is Nearing Completion

Share

The Number Of Job Openings In The U.S. In December Was 6.542 Million, Compared With An Expected 7.2 Million And A Revised 6.928 Million In The Previous Month (originally Reported As 7.146 Million)

Share

U.S. Senate Democratic Member Warren Questioned The Relationship Between Elon Musk's SpaceX And The Pentagon

Share

Brazilian President Lula: May Travel To Washington In The First Week Of March To Meet With US President Trump

Share

Brazil President Lula: Told Trump That Brazil Is Interested In Being Part Of Board Of Peace If Focused Only On Gaza

TIME
ACT
FCST
PREV
Japan 30-Year JGB Auction Yield

A:--

F: --

P: --

Indonesia Annual GDP Growth

A:--

F: --

P: --

Indonesia GDP YoY (Q4)

A:--

F: --

P: --

France Industrial Output MoM (SA) (Dec)

A:--

F: --

P: --
Italy IHS Markit Construction PMI (Jan)

A:--

F: --

P: --

Euro Zone IHS Markit Construction PMI (Jan)

A:--

F: --

P: --

Germany Construction PMI (SA) (Jan)

A:--

F: --

P: --

Italy Retail Sales MoM (SA) (Dec)

A:--

F: --

P: --

U.K. Markit/CIPS Construction PMI (Jan)

A:--

F: --

P: --

France 10-Year OAT Auction Avg. Yield

A:--

F: --

P: --

Euro Zone Retail Sales YoY (Dec)

A:--

F: --

P: --
Euro Zone Retail Sales MoM (Dec)

A:--

F: --

P: --
U.K. BOE MPC Vote Cut (Feb)

A:--

F: --

P: --

U.K. BOE MPC Vote Hike (Feb)

A:--

F: --

P: --

U.K. BOE MPC Vote Unchanged (Feb)

A:--

F: --

P: --

U.K. Benchmark Interest Rate

A:--

F: --

P: --

MPC Rate Statement
U.S. Challenger Job Cuts (Jan)

A:--

F: --

P: --

U.S. Challenger Job Cuts MoM (Jan)

A:--

F: --

P: --

U.S. Challenger Job Cuts YoY (Jan)

A:--

F: --

P: --

Bank of England Governor Bailey held a press conference on monetary policy.
Euro Zone ECB Marginal Lending Rate

A:--

F: --

P: --

Euro Zone ECB Deposit Rate

A:--

F: --

P: --

Euro Zone ECB Main Refinancing Rate

A:--

F: --

P: --

ECB Monetary Policy Statement
U.S. Weekly Initial Jobless Claims (SA)

A:--

F: --

P: --

U.S. Initial Jobless Claims 4-Week Avg. (SA)

A:--

F: --

P: --

U.S. Weekly Continued Jobless Claims (SA)

A:--

F: --

P: --
ECB Press Conference
U.S. JOLTS Job Openings (SA) (Dec)

A:--

F: --

P: --
U.S. EIA Weekly Natural Gas Stocks Change

--

F: --

P: --

BOC Gov Macklem Speaks
Mexico Policy Interest Rate

--

F: --

P: --

U.S. Weekly Treasuries Held by Foreign Central Banks

--

F: --

P: --

Reserve Bank of Australia Governor Bullock testified before Parliament.
India Benchmark Interest Rate

--

F: --

P: --

India Cash Reserve Ratio

--

F: --

P: --

India Repo Rate

--

F: --

P: --

India Reverse Repo Rate

--

F: --

P: --

Japan Leading Indicators Prelim (Dec)

--

F: --

P: --

Germany Industrial Output MoM (SA) (Dec)

--

F: --

P: --

Germany Exports MoM (SA) (Dec)

--

F: --

P: --

U.K. Halifax House Price Index YoY (SA) (Jan)

--

F: --

P: --

U.K. Halifax House Price Index MoM (SA) (Jan)

--

F: --

P: --

France Trade Balance (SA) (Dec)

--

F: --

P: --

Canada Leading Index MoM (Jan)

--

F: --

P: --

India Deposit Gowth YoY

--

F: --

P: --

Canada Employment (SA) (Jan)

--

F: --

P: --
Canada Full-time Employment (SA) (Jan)

--

F: --

P: --
Canada Part-Time Employment (SA) (Jan)

--

F: --

P: --
Canada Unemployment Rate (SA) (Jan)

--

F: --

P: --

Canada Labor Force Participation Rate (SA) (Jan)

--

F: --

P: --

U.S. Unemployment Rate (SA) (Jan)

--

F: --

P: --

U.S. Nonfarm Payrolls (SA) (Jan)

--

F: --

P: --

U.S. Average Hourly Wage YoY (Jan)

--

F: --

P: --

U.S. Average Hourly Wage MoM (SA) (Jan)

--

F: --

P: --

U.S. U6 Unemployment Rate (SA) (Jan)

--

F: --

P: --

U.S. Manufacturing Employment (SA) (Jan)

--

F: --

P: --

U.S. Labor Force Participation Rate (SA) (Jan)

--

F: --

P: --

U.S. Average Weekly Working Hours (SA) (Jan)

--

F: --

P: --

U.S. Private Nonfarm Payrolls (SA) (Jan)

--

F: --

P: --

Q&A with Experts
    • All
    • Chatrooms
    • Groups
    • Friends
    SlowBear ⛅ flag
    Nawhdir Øt
    @Nawhdir Øt you keep Making money without me bro, when you become a billionaire from that single trade I will come and loan $5mil from you
    0VP7MQ5LZJ flag
    SlowBear ⛅
    @SlowBear ⛅kkk
    EuroTrader flag
    0VP7MQ5LZJ
    @0VP7MQ5LZJwhat pair are you on the lookout for at the moment bro
    Nawhdir Øt flag
    EuroTrader flag
    Nawhdir Øt
    @Nawhdir ØtU.S. JOLTS Job Openings (SA) (Dec) Act:6.542M,Prev:6.928M,Fcst:7.2M https://m.fastbull.com/en/calendar-detail/833622-1?shareType=2&calendarId=833622&unscrambleId=fb_ljy_634&releasedDate=1770303600000&calendarType=0 bad jolt means USD should sell off right and XXXUSD rally
    Nawhdir Øt flag
    EuroTrader
    @EuroTraderah, I'm in the BTC/USD room
    Sanjeev Ku flag
    Sanjeev Ku
    btc 69335 gone open for 65676. selling continues in btc .low 67266
    SlowBear ⛅ flag
    0VP7MQ5LZJ
    @0VP7MQ5LZJ alright boss, let’s stay open and watch the market closely
    SlowBear ⛅ flag
    Nawhdir Øt
    @Nawhdir Øt boss are you sure you want to keep those buy limit there?
    EuroTrader flag
    Nawhdir Øt
    @Nawhdir ØtBitcoin is trading like an accursed pair. it hitting new lows by the day cousin
    Mxgold flag
    SlowBear ⛅
    @SlowBear ⛅agree
    Sanjeev Ku flag
    Sanjeev Ku flag
    gold
    SlowBear ⛅ flag
    EuroTrader
    But, what he shared was btc bro? Not sure how Jolts, Btc and Gold are related IMO
    SlowBear ⛅ flag
    Mxgold
    @Mxgold cool one bro, so are you in any trade yet? Or you are still waiting
    Charizard flag
    Sanjeev Ku
    gold
    @Sanjeev Ku Why is it refusing to find the drop off right now?
    EuroTrader flag
    SlowBear ⛅
    not related but at least a knee jerk reaction of some sort..it's in a world of uts own
    Nawhdir Øt flag
    SlowBear ⛅
    @SlowBear ⛅sure
    Nawhdir Øt flag
    Nawhdir Øt
    I remain dynamic if shifting is necessary
    Nawhdir Øt flag
    Type here...
    Add Symbol or Code

      No matching data

      All
      Trump Updates
      Recommend
      Stocks
      Cryptocurrencies
      Central Banks
      Featured News
      • All
      • Russia-Ukraine Conflict
      • Middle East Flashpoint
      • All
      • Russia-Ukraine Conflict
      • Middle East Flashpoint
      Search
      Products

      Charts Free Forever

      Chats Q&A with Experts
      Screeners Economic Calendar Data Tools
      Membership Features
      Data Warehouse Market Trends Institutional Data Policy Rates Macro

      Market Trends

      Market Sentiment Order Book Forex Correlations

      Top Indicators

      Charts Free Forever
      Markets

      News

      News Analysis 24/7 Columns Education
      From Institutions From Analysts
      Topics Columnists

      Latest Views

      Latest Views

      Trending Topics

      Top Columnists

      Latest Update

      Signals

      Copy Rankings Latest Signals Become a signal provider AI Rating
      Contests
      Brokers

      Overview Brokers Assessment Rankings Regulators News Claims
      Broker listing Forex Brokers Comparison Tool Live Spread Comparison Scam
      Q&A Complaint Scam Alert Videos Tips to Detect Scam
      More

      Business
      Events
      Careers About Us Advertising Help Center

      White Label

      Broker API

      Data API

      Web Plug-ins

      Affiliate Program

      Awards Institution Evaluation IB Seminar Salon Event Exhibition
      Vietnam Thailand Singapore Dubai
      Fans Party Investment Sharing Session
      FastBull Summit BrokersView Expo
      Recent Searches
        Top Searches
          Markets
          News
          Analysis
          User
          24/7
          Economic Calendar
          Education
          Data
          • Names
          • Latest
          • Prev

          View All

          No data

          Scan to Download

          Faster Charts, Chat Faster!

          Download App
          English
          • English
          • Español
          • العربية
          • Bahasa Indonesia
          • Bahasa Melayu
          • Tiếng Việt
          • ภาษาไทย
          • Français
          • Italiano
          • Türkçe
          • Русский язык
          • 简中
          • 繁中
          Open Account
          Search
          Products
          Charts Free Forever
          Markets
          News
          Signals

          Copy Rankings Latest Signals Become a signal provider AI Rating
          Contests
          Brokers

          Overview Brokers Assessment Rankings Regulators News Claims
          Broker listing Forex Brokers Comparison Tool Live Spread Comparison Scam
          Q&A Complaint Scam Alert Videos Tips to Detect Scam
          More

          Business
          Events
          Careers About Us Advertising Help Center

          White Label

          Broker API

          Data API

          Web Plug-ins

          Affiliate Program

          Awards Institution Evaluation IB Seminar Salon Event Exhibition
          Vietnam Thailand Singapore Dubai
          Fans Party Investment Sharing Session
          FastBull Summit BrokersView Expo

          Pasithea Therapeutics Initiated at Buy by HC Wainwright & Co.

          Dow Jones Newswires
          Pasithea Therapeutics
          +1.19%
          Pasithea Therapeutics Corp. Warrants
          0.00%
          This news item displays a headline only and has no other text.
          Risk Warnings and Disclaimers
          You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.
          Add to Favorites
          Share

          U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.67%

          Investing.com
          Meta Platforms
          -1.54%
          Pasithea Therapeutics
          +1.19%
          Kaixin Holdings
          -9.62%
          MingZhu Logistics
          0.00%
          SMX (Security Matters)
          -10.79%

          Investing.com – U.S. stocks were higher after the close on Wednesday, as gains in the Basic Materials, Utilities and Consumer Goods sectors led shares higher.

          At the close in NYSE, the Dow Jones Industrial Average added 0.67%, while the S&P 500 index added 0.69%, and the NASDAQ Composite index added 0.82%.

          The best performers of the session on the Dow Jones Industrial Average were Boeing Co (NYSE:BA), which rose 2.46% or 4.48 points to trade at 186.92 at the close. Meanwhile, Walmart Inc (NYSE:WMT) added 1.97% or 2.10 points to end at 109.10 and Microsoft Corporation (NASDAQ:MSFT) was up 1.78% or 8.51 points to 485.50 in late trade.

          The worst performers of the session were Salesforce Inc (NYSE:CRM), which fell 2.55% or 5.97 points to trade at 228.15 at the close. Merck & Company Inc (NYSE:MRK) declined 0.97% or 1.03 points to end at 104.63 and Honeywell International Inc (NASDAQ:HON) was down 0.54% or 1.03 points to 189.99.

          The top performers on the S&P 500 were Teradyne Inc (NASDAQ:TER) which rose 6.98% to 179.38, Dell Technologies Inc (NYSE:DELL) which was up 5.83% to settle at 133.26 and Newmont Goldcorp Corp (NYSE:NEM) which gained 4.93% to close at 90.52.

          The worst performers were Deere & Company (NYSE:DE) which was down 5.76% to 469.46 in late trade, Intuit Inc (NASDAQ:INTU) which lost 2.94% to settle at 629.02 and ServiceNow Inc (NYSE:NOW) which was down 2.74% to 802.72 at the close.

          The top performers on the NASDAQ Composite were Lion Group Holding Ltd (NASDAQ:LGHL) which rose 1,543.33% to 7.12, SMX Security Matters Ord Shs Class A (NASDAQ:SMX) which was up 194.42% to settle at 17.40 and Pasithea Therapeutics Corp (NASDAQ:KTTA) which gained 117.39% to close at 1.06.

          The worst performers were Lazydays Holdings Inc (NASDAQ:GORV) which was down 45.31% to 0.42 in late trade, Mingzhu Logistics Holdings Ltd (NASDAQ:YGMZ) which lost 34.15% to settle at 0.12 and Kaixin Auto Holdings (NASDAQ:KXIN) which was down 30.83% to 0.14 at the close.

          Rising stocks outnumbered declining ones on the New York Stock Exchange by 1923 to 819 and 94 ended unchanged; on the Nasdaq Stock Exchange, 2108 rose and 1275 declined, while 148 ended unchanged.

          Shares in Walmart Inc (NYSE:WMT) rose to all time highs; up 1.97% or 2.10 to 109.10. Shares in Lazydays Holdings Inc (NASDAQ:GORV) fell to all time lows; down 45.31% or 0.35 to 0.42. Shares in Mingzhu Logistics Holdings Ltd (NASDAQ:YGMZ) fell to all time lows; losing 34.15% or 0.06 to 0.12. Shares in Kaixin Auto Holdings (NASDAQ:KXIN) fell to all time lows; down 30.83% or 0.06 to 0.14.

          The CBOE Volatility Index, which measures the implied volatility of S&P 500 options, was down 7.33% to 17.20.

          Gold Futures for February delivery was up 0.76% or 31.60 to $4,196.80 a troy ounce. Elsewhere in commodities trading, Crude oil for delivery in January rose 0.83% or 0.48 to hit $58.59 a barrel, while the February Brent oil contract rose 1.07% or 0.66 to trade at $62.46 a barrel.

          EUR/USD was unchanged 0.22% to 1.16, while USD/JPY rose 0.26% to 156.46.

          The US Dollar Index Futures was down 0.07% at 99.52.

          Risk Warnings and Disclaimers
          You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.
          Add to Favorites
          Share

          U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.44%

          Investing.com
          Carnival
          -1.20%
          Broadcom
          +1.88%
          Cboe Global Markets
          +1.43%
          Antelope Enterprise
          -12.37%
          Apple
          -0.32%

          Investing.com – U.S. stocks were higher after the close on Monday, as gains in the Technology, Consumer Goods and Utilities sectors led shares higher.

          At the close in NYSE, the Dow Jones Industrial Average rose 0.44%, while the S&P 500 index climbed 1.55%, and the NASDAQ Composite index climbed 2.69%.

          The best performers of the session on the Dow Jones Industrial Average were Merck & Company Inc (NYSE:MRK), which rose 2.70% or 2.64 points to trade at 100.40 at the close. Meanwhile, Amazon.com Inc (NASDAQ:AMZN) added 2.44% or 5.38 points to end at 226.07 and International Business Machines (NYSE:IBM) was up 2.25% or 6.70 points to 304.14 in late trade.

          The worst performers of the session were Procter & Gamble Company (NYSE:PG), which fell 2.61% or 3.94 points to trade at 146.98 at the close. Verizon Communications Inc (NYSE:VZ) declined 2.47% or 1.02 points to end at 40.21 and Walt Disney Company (NYSE:DIS) was down 2.25% or 2.35 points to 101.94.

          The top performers on the S&P 500 were Broadcom Inc (NASDAQ:AVGO) which rose 11.10% to 377.96, Western Digital Corporation (NASDAQ:WDC) which was up 8.43% to settle at 150.93 and Micron Technology Inc (NASDAQ:MU) which gained 7.99% to close at 223.93.

          The worst performers were Carnival Corporation (NYSE:CCL) which was down 6.78% to 24.76 in late trade, Paramount Skydance Corp (NASDAQ:PSKY) which lost 5.22% to settle at 15.06 and Copart Inc (NASDAQ:CPRT) which was down 4.47% to 38.91 at the close.

          The top performers on the NASDAQ Composite were Meihua International Medical Technologies Co Ltd (NASDAQ:MHUA) which rose 8,103.58% to 11.93, Antelope Enterprise Holdings Ltd (NASDAQ:AEHL) which was up 108.26% to settle at 2.52 and Pasithea Therapeutics Corp (NASDAQ:KTTA) which gained 48.53% to close at 0.43.

          The worst performers were Clearside Biomedical Inc (NASDAQ:CLSD) which was down 66.92% to 0.90 in late trade, Twin Hospitality Group Inc (NASDAQ:TWNP) which lost 39.44% to settle at 2.15 and Mobilehealth Network Solutions (NASDAQ:MNDR) which was down 38.53% to 2.92 at the close.

          Rising stocks outnumbered declining ones on the New York Stock Exchange by 1721 to 1034 and 82 ended unchanged; on the Nasdaq Stock Exchange, 2194 rose and 1181 declined, while 153 ended unchanged.

          Shares in Copart Inc (NASDAQ:CPRT) fell to 52-week lows; falling 4.47% or 1.82 to 38.91. Shares in Meihua International Medical Technologies Co Ltd (NASDAQ:MHUA) rose to 3-years lows; gaining 8,103.58% or 11.78 to 11.93. Shares in Clearside Biomedical Inc (NASDAQ:CLSD) fell to all time lows; losing 66.92% or 1.82 to 0.90. Shares in Twin Hospitality Group Inc (NASDAQ:TWNP) fell to all time lows; losing 39.44% or 1.40 to 2.15.

          The CBOE Volatility Index, which measures the implied volatility of S&P 500 options, was down 12.46% to 20.51.

          Gold Futures for February delivery was up 1.21% or 49.70 to $4,165.70 a troy ounce. Elsewhere in commodities trading, Crude oil for delivery in January rose 2.02% or 1.17 to hit $58.98 a barrel, while the February Brent oil contract rose 1.42% or 0.88 to trade at $62.82 a barrel.

          EUR/USD was unchanged 0.06% to 1.15, while USD/JPY rose 0.33% to 156.90.

          The US Dollar Index Futures was up 0.01% at 100.12.

          Risk Warnings and Disclaimers
          You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.
          Add to Favorites
          Share

          Pasithea Therapeutics stock plunges after Phase 1 interim data release

          Investing.com
          Alphabet-A
          -5.03%
          Meta Platforms
          -1.54%
          Amazon
          -4.67%
          Advanced Micro Devices
          -3.30%
          Pasithea Therapeutics
          +1.19%

          Investing.com -- Pasithea Therapeutics Corp (NASDAQ:KTTA) stock plummeted 25% in after-hours trading Thursday following the release of interim Phase 1 data for its MEK inhibitor PAS-004.

          The clinical-stage biotech company reported initial results from its first-in-human trial evaluating PAS-004 in patients with MAPK pathway-driven advanced solid tumors. Despite the company highlighting a partial response in one melanoma patient and a disease control rate of 71.4% in patients with BRAF-mutated tumors, investors appeared unimpressed with the overall efficacy profile.

          The trial data showed that among 21 efficacy-evaluable patients, only one achieved a partial response - a BRAF V600E melanoma patient who showed a 31.9% tumor reduction and remains on trial for over 11 months. A second melanoma patient achieved stable disease with minimal tumor shrinkage of 1.6% after six months of treatment.

          Pasithea reported that PAS-004 demonstrated a favorable safety profile with all treatment-related adverse events being Grade 1 or 2, with no ocular or cardiovascular toxicities observed. Common side effects included nausea (18.5%), vomiting (14.8%), rash (7.4%), and diarrhea (7.4%).

          The company is developing PAS-004 as a potential treatment for neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN). The drug showed dose-proportional pharmacokinetics with an AUC of approximately 5,480 ng·h/mL at the 30mg capsule dose.

          Despite management’s optimistic interpretation of the data, the significant stock decline suggests investors had expected stronger efficacy signals from this interim readout.

          This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

          Risk Warnings and Disclaimers
          You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.
          Add to Favorites
          Share

          Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board

          GlobeNewswire
          Pasithea Therapeutics
          +1.19%
          Pasithea Therapeutics Corp. Warrants
          0.00%

          MIAMI, June 11, 2025 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced the appointment of Dr. James Lee to its scientific advisory board (SAB) to help guide development of PAS-004 for the treatment of ETS2 pathway inflammatory diseases including inflammatory bowel disease (IBD), ulcerative colitis, Crohn’s disease, primary sclerosing cholangitis and ankylosing spondylitis.

          Dr. Lee is the lead author on a 2024 Nature publication that identified ETS2 as a central regulator of macrophage-driven inflammation in IBD and other indications, and also identified that MEK inhibitors are the drug class that most effectively suppress ETS2-driven inflammation.

          “Dr. Lee’s clinical research has deepened the field’s understanding of the ETS2 pathway in inflammatory diseases and has the potential to lead to transformative therapies for patients with IBD,” commented Pasithea CEO, Dr. Tiago Reis Marques. “We expect Dr. Lee’s guidance will be central to the expansion of PAS-004’s development to additional indications beyond NF1, which we plan to fund through non-dilutive financing, including grants and/or strategic collaborations.”

          Dr. James Lee is a Clinician Scientist Group Leader at the Francis Crick Institute (London, UK) and an Honorary Consultant Gastroenterologist at the Royal Free Hospital. He has clinical expertise in inflammatory bowel disease (IBD) and is also an active member of the UK and International IBD Genetics Consortia.

          Dr Lee trained at Oxford, Cambridge, and Harvard and leads a research group that seeks to translate genetic associations into a better understanding of autoimmune and inflammatory disease biology. His research is internationally renowned with publications in such scientific journals as Nature and Cell.

          About Pasithea Therapeutics Corp.

          Pasithea is a clinical-stage biotechnology company primarily focused on the research and development of its lead drug candidate, PAS-004, a next-generation macrocyclic MEK inhibitor intended for the treatment of RASopathies, MAPK pathway-driven tumors, and other diseases. The Company is currently testing PAS-004 in a Phase 1 clinical trial in advanced cancer patients (NCT06299839), and a Phase 1/1b clinical trial in adult patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (NCT06961565).

          Forward Looking Statements

          This press release contains statements that constitute “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the Company’s ongoing Phase 1 clinical trial of PAS-004 in advanced cancer patients, the Company’s Phase 1/1b clinical trial of PAS-004 in adult NF1 patients, and the safety, tolerability, pharmacokinetic (PK), pharmacodynamics (PD) and preliminary efficacy of PAS-004, as well as all other statements, other than statements of historical fact, regarding the Company’s current views and assumptions with respect to future events regarding its business, as well as other statements with respect to the Company’s plans, assumptions, expectations, beliefs and objectives, the success of the Company’s current and future business strategies, product development, pre-clinical studies, clinical studies, clinical and regulatory timelines, market opportunity, competitive position, business strategies, potential growth and financing opportunities and other statements that are predictive in nature. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the Company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including risks that future clinical trial results may not match results observed to date, may be negative or ambiguous, or may not reach the level of statistical significance required for regulatory approval, as well as other factors set forth in the Company’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and other filings made with the U.S. Securities and Exchange Commission (SEC). Thus, actual results could be materially different. The Company undertakes no obligation to update these statements whether as a result of new information, future events or otherwise, after the date of this release, except as required by law.

          Pasithea Therapeutics Contact

          Patrick Gaynes

          Corporate Communications

          pgaynes@pasithea.com

          Risk Warnings and Disclaimers
          You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.
          Add to Favorites
          Share

          Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025

          GlobeNewswire
          Pasithea Therapeutics
          +1.19%
          Pasithea Therapeutics Corp. Warrants
          0.00%
          Risk Warnings and Disclaimers
          You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.
          Add to Favorites
          Share

          Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases

          GlobeNewswire
          Pasithea Therapeutics
          +1.19%
          Pasithea Therapeutics Corp. Warrants
          0.00%
          Risk Warnings and Disclaimers
          You understand and acknowledge that there is a high degree of risk involved in trading. Following any strategies or investment methods may lead to potential losses. The content on the site is provided by our contributors and analysts for information purposes only. You are solely responsible for determining whether any trading assets, securities, strategy, or any other product is suitable for investing based on your own investment objectives and financial situation.
          Add to Favorites
          Share
          FastBull
          Copyright © 2026 FastBull Ltd

          728 RM B 7/F GEE LOK IND BLDG NO 34 HUNG TO RD KWUN TONG KLN HONG KONG

          TelegramInstagramTwitterfacebooklinkedin
          App Store Google Play Google Play
          Products
          Charts

          Chats

          Q&A with Experts
          Screeners
          Economic Calendar
          Data
          Tools
          Membership
          Features
          Function
          Markets
          Copy Trading
          Latest Signals
          Contests
          News
          Analysis
          24/7
          Columns
          Education
          Company
          Careers
          About Us
          Contact Us
          Advertising
          Help Center
          Feedback
          User Agreement
          Privacy Policy
          Personal Information Protection Statement
          Business

          White Label

          Broker API

          Data API

          Web Plug-ins

          Poster Maker

          Affiliate Program

          Risk Disclosure

          The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.

          No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.

          Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.

          Not Logged In

          Log in to access more features

          Connect Broker
          Become a signal provider
          Help Center
          Customer Service
          Dark Mode
          Price Up/Down Colors

          Log In

          Sign Up

          Position
          Layout
          Fullscreen
          Default to Chart
          The chart page opens by default when you visit fastbull.com